Discontinuing antidepressants: Pearls and pitfalls

ABSTRACT

Stopping antidepressants can be challenging due to the high rate of discontinuation symptoms. Patients with antidepressant discontinuation syndrome (ADS) commonly experience insomnia, flu-like symptoms, mood disturbances, dizziness, and paresthesias, but a broad array of adverse effects is possible. Symptoms can last for days to months, and different symptoms have different durations. Patient education, identification of patients most at risk for developing symptoms, and a slow antidepressant taper or cross-taper are important steps in mitigating the risk of ADS and managing patient concerns about ADS. Tapers should be carried out over weeks to months. Discontinuation symptoms should be managed with restarting the prior dose of antidepressant and then tapering even more slowly, with additional symptomatic management as needed.

KEY POINTS

Changing or stopping antidepressants, especially if done abruptly, can be associated with ADS. Symptoms can present within hours and last for months due to the complex mechanisms of antidepressants. Slow tapers should be carried out over weeks to months to minimize the risk of ADS. Knowing risk factors for ADS can identify the most vulnerable patients.

AN EVER-INCREASING NUMBER OF PATIENTS are prescribed antidepressant medications, most often by primary care physicians, with approximately 12.7% of the adult population in the United States prescribed a daily antidepressant. Antidepressants are used to treat a variety of conditions other than mood and anxiety disorders, such as chronic pain syndromes, tobacco use disorder, and obsessive-compulsive disorder. Common scenarios prompting discontinuation of an antidepressant include the following:

• The condition for which the antidepressant was started is in remission for an appropriate maintenance period
• The antidepressant does not achieve a satisfactory effect
• Intolerable side effects emerge
• New drug-drug interactions occur due to additional medication the patient must take
• The patient’s prescription drug insurance coverage changes.

In the case of insurance coverage, clinicians are encouraged to advocate for the patient whenever a coverage issue arises in order to avoid changing antidepressants. Additionally, patients may choose to stop an antidepressant of their own accord.

Stopping antidepressants can be challenging because of the frequency of antidepressant discontinuation syndrome (ADS). Discontinuation symptoms occur commonly and vary in severity. Symptoms will often surprise and frighten patients who are not forewarned, leading them to seek emergency medical care. Discontinuation symptoms include insomnia, flu-like symptoms, mood disturbances, dizziness, paresthesias (“brain zaps”), and a broad array of other adverse effects.
The range of risk factors for ADS indicates the complex mechanisms underlying discontinuation symptoms beyond acute medication cessation. But despite the frequent morbidity associated with stopping antidepressants, there is a notable lack of guidance for clinicians on tapering antidepressants or managing ADS, and the majority of available guidelines are not considered evidence-based. The following narrative review describes the array of discontinuation symptoms and their causes and provides practical clinical guidance for discontinuing antidepressants to minimize the risk of ADS. The principles discussed regarding medication discontinuation and switching to another antidepressant can be applied regardless of the antidepressant indication.

### Symptoms and Risk of Antidepressant Discontinuation

ADS can pose diagnostic challenges because many symptoms of discontinuation overlap with those of toxicity and recurrence. ADS should be suspected if the patient reports either new symptoms that were not part of the original presentation or symptoms noted in the original presentation but at greater severity. ADS can be conceptualized into 3 categories: acute withdrawal (new symptoms for < 6 weeks), rebound (same symptoms with greater severity for < 6 weeks), and persistent withdrawal (new symptoms or same symptoms with greater severity for > 6 weeks). By contrast, new episodes of the original condition can occur after discontinuation, including relapse (same symptoms at the same severity emerge < 6 weeks) and recurrence (same symptoms at the same severity emerge > 6 months). These definitions are summarized in Table 1.

| Condition | Category | Onset, duration | Symptoms |
|-----------|----------|-----------------|----------|
| Discontinuation syndrome | Acute withdrawal | Onset 36–96 hours Duration < 6 weeks | New symptoms not present before antidepressant was started or stopped |
| | Rebound | Onset 36–96 hours Duration < 6 weeks | Greater severity of original symptoms |
| | Persistent withdrawal syndrome | Onset 24 hours to 6 weeks Duration > 6 weeks | New symptoms and/or greater severity of original symptoms |
| New episode | Relapse | Onset < 6 weeks Duration variable | Original symptoms at original severity |
| | Recurrence | Onset > 6 months Duration variable | Original symptoms at original severity |

Based on information in reference 9.

### Risk of Relapse

Patients who stop antidepressants, regardless of the specific psychiatric indication or duration of taper, are at a greater risk of relapse of psychiatric illness than those patients who remain on antidepressants. A large meta-analysis found the rate of 12-month relapse was 2.3 times higher in patients who had stopped antidepressants compared with those who continued treatment. Of patients who stopped antidepressants, 44.8% experienced a relapse or recurrence within 12 months compared with 19.5% of patients who continued antidepressants. The patients who stopped antidepressants also demonstrated a median time...
DISCONTINUING ANTIDEPRESSANTS

to recurrence of about 14 months, compared with 48 months for patients who continued antidepressants. Therefore, it is especially critical to distinguish between a recurrent episode and ADS.

Studies have shown that 27% to 86% of patients who attempt to stop antidepressants, whether on their own or under supervision of a physician, experience ADS. One review included studies ranging from randomized clinical trials to online surveys, with a weighted average of 56%. Of patients experiencing discontinuation symptoms, 86.7% reported ongoing symptoms at 2 months, 58.6% at 1 year, and 16.2% beyond 3 years. Persistent discontinuation symptoms, often termed protracted withdrawal syndrome, is not formally defined but should be diagnosed when discontinuation symptoms persist beyond several months. Data from an Internet forum for patients identified a mean duration of 37 months and a median duration of 26 months in persistent symptoms. Of forum users identified as having protracted withdrawal, 73.9% experienced various physical symptoms, 82.6% experienced affective symptoms, and 63.8% experienced both physical and affective symptoms. Sleep disturbances (43.5%) and cognitive symptoms (31.9%) were also very common. 

Symptoms vary by drug class
Symptoms of ADS present across a range of organ systems and vary based on the antidepressant class and individual medication. Table 2 summarizes the most typical symptoms, though symptoms can vary by individual medication since many medications, even within the same class, have different receptor profiles and affinities. There is relatively little information available on tricyclics, tetracyclics, and monoamine oxidase inhibitors (MAOIs) relative to selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), in part because symptoms were often thought to be psychosomatic and not of much importance at a time when tricyclics, tetracyclics, and MAOIs were more commonly used.

Brain zaps: Unpleasant, sometimes disabling
Another notable discontinuation symptom is a type of paresthesia known colloquially as “brain zaps,” unpleasant and sometimes disabling electric shock-like sensations. These sensations may be due to adrenergic withdrawal. Therefore, SNRIs are expected to have a higher likelihood of causing brain zaps than SSRIs. Disproportionately higher rates of brain zaps are reported with venlafaxine but also with paroxetine, and they have been reported with many antidepressants.

A useful diagnostic mnemonic
To simplify recognition of ADS, clinicians can use the mnemonic FINISH for flu-like symptoms, insomnia, nausea, imbalance (dizziness), sensory disturbances (parasthesias, including brain zaps), and hyperarousal (anxiety, irritability), which are fairly generalizable across antidepressant classes.

Suicidal ideation, panic, and other risks
Discontinuation of antidepressants can carry significant risk, including suicidal ideation, suicide, and mania. One study of 73 patients investigating the role of adjunctive psychotherapy in antidepressant discontinuation had to be stopped due to ethical concerns stemming from lack of efficacy and a patient suicide. Another study observed 28 patients undergoing antidepressant discontinuation and found suicidal ideation in 4 patients, all of whom were stopping paroxetine.

Panic and restlessness due to ADS likely exacerbate suicidal ideation, which in most cases is probably due to ADS rather than relapse. Patients treated for panic disorder should be closely monitored for rebound.

Cessation of antidepressants can also elicit mania or hypomania. Although it is more frequent that patients experience depression following antidepressant discontinuation, the phenomenon of mania due to antidepressant cessation has been observed in at least 24 cases across various antidepressants.

Brain zaps: Unpleasant, sometimes disabling
Another notable discontinuation symptom is a type of paresthesia known colloquially as “brain zaps,” unpleasant and sometimes disabling electric shock-like sensations. These sensations may be due to adrenergic withdrawal. Therefore, SNRIs are expected to have a higher likelihood of causing brain zaps than SSRIs. Disproportionately higher rates of brain zaps are reported with venlafaxine but also with paroxetine, and they have been reported with many antidepressants.

Electric shock-like sensations are most often seen in patients who have abruptly stopped antidepressant treatment or missed doses, though more than 30% of patients with brain zaps report these symptoms either while undergoing a taper or after completing a taper. Some patients may experience the zaps during normal treatment.
### TABLE 2

Discontinuation symptoms by antidepressant drug class

| System       | SSRIs                  | SNRIs                  | TCAs                  | MAOIs                  | Atypicals                  |
|--------------|------------------------|------------------------|-----------------------|-------------------------|----------------------------|
| General      | Flu-like symptoms      | Flu-like symptoms      | Flu-like symptoms      | Flu-like symptoms        | Flu-like symptoms          |
|              | Fatigue                | Fatigue                | Fatigue               | Fatigue                 | Fatigue                   |
| Cardiovascular | Tachycardia            | Tachycardia            | Tachycardia           | Tachycardia             | (Limited data)             |
|              | Flushing               | Hypertension, hypotension | Arrhythmia            |                         |                            |
| Gastrointestinal | Nausea, vomiting      | Nausea, vomiting      | Nausea, vomiting      | Nausea, vomiting        | Nausea, vomiting           |
|              | Diarrhea               | Diarrhea               | Diarrhea              | Diarrhea                | Diarrhea                  |
|              | Anorexia               | Anorexia               | Anorexia              | Anorexia                | Anorexia (mirtazapine)     |
| Neurologic   | Headache               | Headache               | Headache              | Headache                | Headache                  |
|              | Gait instability       | Gait instability       | Paresthesias, tremor  | Paresthesias            | Dizziness                 |
|              | Dizziness              | Dizziness              | tremor, ataxia        | Tremor, ataxia          | Paresthesias, tremor       |
|              | Paresthesias, brain zaps | Parasthesias, brain zaps | Seizure               | Seizure, myoclonus      | Tremor                     |
|              | Tremor, ataxia         | Tremor, ataxia         | Stroke-like symptoms  | Parkinsonism            | Dystonia                   |
|              | Myoclonus, muscle jerking | Stroke-like symptoms  | Seizure, myoclonus    | Parkinsonism            | Dystonia                   |
|              | Parkinsonism           | Parkinsonism           | Muscle jerking        |                         | Catatonic                  |
| Psychiatric  | Anxiety, panic         | Anxiety, panic         | Anxiety, panic        | Depression, lability    | Anxiety, panic             |
|              | Depression, mania      | Depression, mania      | Depression, mania     | Suicidal ideation       | Depression, mania          |
|              | Suicidal ideation      | Suicidal ideation      | Suicidal ideation     | Anger, irritability     | Suicidal ideation          |
|              | Anger, irritability    | Anger, irritability    | Anger, irritability   | Mood swings             | Mood swings                |
|              | Mood swings            | Mood swings            | Mood swings           | Derealization           | Depression, lability       |
|              | Depersonalization, delirium | Depersonalization, delirium | Hallucinations        | Depression, lability    | Depression, lability       |
|              | Confusion, delirium    | Confusion, delirium    | Confusion, delirium   | Depression, lability    | Depression, lability       |
| Cognitive    | Inattention            | Inattention            | Inattention           | Inattention             | Inattention               |
| Sleep        | Sleep disturbances     | Sleep disturbances     | Sleep disturbances    | Sleep disturbances      | Sleep disturbances         |
|              | Nightmares, vivid dreams | Nightmares, vivid dreams | Nightmares, vivid dreams | Nightmares, vivid dreams | Nightmares, vivid dreams   |
| Visual       | Vision changes         | Vision changes         | Vision changes        | Vision changes          | (Limited data)             |
| Sexual       | Dysfunction            | Dysfunction            | Dysfunction           | Dysfunction             | Dysfunction                |

MAOIs = monoamine oxidase inhibitors; SNRIs = serotonin-norepinephrine reuptake inhibitors; SSRIs = selective serotonin reuptake inhibitors; TCAs = tricyclic and tetracyclic antidepressants

Based on information in references 6,7,13,14.
The sensations typically last a few weeks but can persist for years and may be associated with dizziness, the perception of crackling or sizzling noises, and various other symptoms such as depersonalization (feeling detached from and outside of one’s own body) and derealization (the sensation that the external world is unreal). Common triggers are eye and head movements, but patients note many other triggering activities. There are no known treatments that successfully and specifically target brain zaps other than resuming the medication at the previous dose.19

■ DISCONTINUATION SYNDROME VS WITHDRAWAL

There is controversy surrounding the terminology of ADS vs antidepressant withdrawal. While clinically the terms are often used interchangeably, it is important to appreciate the nuanced meaning of each term. Withdrawal from antidepressants may imply addiction.3,20 However, patients do not crave antidepressants, experience intoxication, or exhibit other hallmarks of a substance use disorder, such as using more and more drug despite negative consequences.17 Therefore, clinically, the term discontinuation is preferred over withdrawal. Some other authors argue that the term discontinuation downplays the severity of the emergent symptoms, which can be intensely uncomfortable and impairing.21 These authors strongly favor the use of antidepressant withdrawal because the syndrome of antidepressant discontinuation is consistent with withdrawal from other substances,6,7,21,22 and because antidepressants cause dependence.12

ADS has been clinically recognized for decades,13,23–25 demonstrating emergence of symptoms within days or even hours of abrupt cessation. Clinical trials that transitioned patients on antidepressants to placebo observed discontinuation symptoms, especially in antidepressants with shorter half-lives.23,24 However, many patients experiencing such symptoms are misdiagnosed as experiencing a relapse or a psychosomatic reaction.13,25 With growing recognition of the difficulty in stopping antidepressants, the risk of ADS should be discussed with patients as part of an informed-consent process when starting antidepressants.25

■ THE PHARMACOKINETICS BEHIND DISCONTINUATION SYNDROME

Straightforward pharmacokinetic explanations of discontinuation symptoms are inadequate since symptoms continue to emerge over a period of weeks and can last for months and even years.22 Antidepressants are believed to exert their effect partly through chronic medication exposure leading to receptor downregulation to create a more favorable neurotransmitter-to-receptor ratio.6,7,26–28 It should be noted that each class of antidepressants exerts its effect in different ways; therefore, broad statements about antidepressant mechanisms of action tend to be overgeneralizations. Still, the mechanism of receptor downregulation, which requires weeks to months and may over time contribute to medication desensitization, likely accounts in part for prolonged discontinuation symptoms.12

Furthermore, it is also hypothesized that antidepressants with anticholinergic properties may lead to receptor upregulation rather than downregulation and thus can contribute to desensitization.13 The theory of “oppositional tolerance” incorporates both upregulation and downregulation,22 because discontinuing antidepressants may lead to diverse rebound symptoms due to the widespread distribution of serotonin throughout the body. Oppositional tolerance that develops and increases over time may explain why patients treated with antidepressants at higher doses and for longer periods are at greater risk for ADS.29

■ WHO IS MOST AT RISK OF DISCONTINUATION SYMPTOMS?

Despite extensive literature on ADS, there is still little known about the patient characteristics that pose the most risk.7,14 Nevertheless, though the risk of ADS cannot be eliminated, it can be reduced through awareness of known risk factors (Table 3).6,7,14,23,24,26,28–32 Some patients may have a genetic predisposition,7 although this is yet to be determined. Younger patients may be more at risk, but younger patients are also more likely to abruptly discontinue their antidepressants.30 Patients who report discontinuation symptoms during missed doses are also at higher risk of withdrawal during a taper,28 and pa...
To date, there are only minimal prospective data comparing the risk of ADS with different antidepressants. A recent review concluded that paroxetine and venlafaxine pose the greatest risk among antidepressants most commonly prescribed today. Table 4 stratifies antidepressants by the risk of ADS.

### TABLE 3

**Risk factors for antidepressant discontinuation syndrome**

- Longer duration of treatment
- Higher dose of drug
- Shorter half-life of drug
- Higher receptor affinity of drug
- Younger patient age
- History of discontinuation symptoms
- Abrupt discontinuation
- High-risk medication (see Table 4)

Based on information in references 6, 7, 14, 23, 24, 26, 28–32.

To date, there are only minimal prospective data comparing the risk of ADS with different antidepressants.

### TAPERING TO CHANGE ANTIDEPRESSANT MEDICATIONS

When switching from one antidepressant to another, taper considerations are different. Cross-tapering is generally recommended and can be carried out over 1 to 4 weeks or longer depending on the dosing of the original medication. Cross-tapering involves incrementally decreasing the current antidepressant while incrementally increasing the new antidepressant (Table 4).

Other ways to change antidepressants include starting the new antidepressant immediately after stopping the previous drug (direct switch), starting the new drug after 2 to 3 days off the prior drug (moderate switch), and starting the new drug after 5 half-lives off the prior drug (conservative switch). A direct switch can be considered when changing an SSRI to another SSRI or SNRI at an equivalent dose, unless the current SSRI is at a high...
TABLE 4
Risk of antidepressant discontinuation syndrome (ADS): A summary of antidepressant dosing

| Risk of ADS | Name (brand name)                      | Starting daily dose (mg) | Daily dose range (mg) | Typical dose increment (mg) (conservative dose increment) |
|------------|---------------------------------------|--------------------------|-----------------------|--------------------------------------------------------|
| Low        | Bupropion XL (Wellbutrin XL)*          | 150                      | 150–450               | 150                                                    |
|            | Doxepin (Silenor)                      | 3                        | 3–6                   | 3                                                      |
|            | Fluoxetine (Prozac)*                   | 10                       | 10–80                 | 10                                                     |
|            | Levomilnacipran (Savella)              | 20                       | 20–120                | 40 (20)                                               |
|            | Milnacipran (Fetzima)                  | 25                       | 50–300                | 25–50 (12.5)                                          |
|            | Vilazodone (Viibryd)                   | 10                       | 10–40                 | 10                                                     |
|            | Citalopram (Celexa)                    | 10                       | 10–40                 | 10                                                     |
|            | Escitalopram (Lexapro)                 | 5                        | 5–30                  | 10 (5)                                                |
|            | Mirtazapine (Remeron)                  | 7.5–15                   | 7.5–60                | 15 (7.5)                                              |
| Intermediate| Sertraline (Zoloft)                    | 25                       | 25–300                | 50 (12.5–25)                                          |
|            | Trazodone (Deseryl)                    | 25–50                    | 25–400                | 50 (25)                                               |
|            | Vortioxetine (Trintellix)              | 5                        | 5–20                  | 5                                                      |
|            | Amitriptyline (Elavil)                 | 10–25                    | 10–300                | 50 (10–25)                                            |
|            | Clomipramine (Anafranil)               | 25                       | 25–300                | 50 (25)                                               |
|            | Desipramine (Norpramin)                | 25                       | 25–300                | 25–50 (10–25)                                         |
|            | Desvenlafaxine (Pristiq)               | 25                       | 50–400                | 50 (25)                                               |
|            | Doxepin (Sinequan)                     | 25                       | 25–300                | 25–50 (10–25)                                         |
|            | Duloxetine DR (Cymbalta DR)            | 20–30                    | 30–120                | 30 (20)                                               |
| High       | Fluvoxamine (Luvox)*                   | 25                       | 25–300                | 50 (12.5–25)                                          |
|            | Imipramine (Tofranil)                  | 25                       | 25–300                | 25–50 (10–25)                                         |
|            | Nortriptyline (Pamelor)                | 10–50                    | 10–150                | 25–50 (10–25)                                         |
|            | Paroxetine (Paxil)*                    | 10                       | 10–50                 | 10 (5)                                                |
|            | Phenelzine (Nardil)                    | 15                       | 7.5–90                | 15                                                     |
|            | Tranylcypromine (Parnate)              | 10                       | 10–60                 | 10                                                     |
|            | Venlafaxine ER (Effexor ER)            | 37.5                     | 75–375                | 37.5                                                   |

Notes:
- *Potent CYP 2D6 inhibitor.
- bPotent CYP 1A2 inhibitor.

dose. Moderate and conservative switches carry the risk of ADS due to the time spent completely off an antidepressant. Alternatively, cross-tapering carries the risk of causing drug-drug interactions, and clinicians should be aware of potential risks such as serotonin syndrome. None of these switching methods are appropriate for MAOIs, which require a 14-day washout both pre- and post-treatment, and at least a 5-week washout if MAOI treatment is preceded by fluoxetine. Studies have suggested discontinuing antidepressants by switching patients to fluoxetine due to its 7-day half-life and rela-
tively low risk of ADS. There are no formal guidelines on fluoxetine-assisted tapers, but the strategy consists of cross-tapering to fluoxetine (slowly decreasing the original antidepressant while increasing fluoxetine to a dosing required for ADS remission) followed by discontinuation of fluoxetine, which can self-taper due to its long half-life. Such a strategy can be helpful when tapering off venlafaxine, desvenlafaxine, paroxetine, and tricyclic and tetracyclic antidepressants. However, clinicians must be wary of drug-drug interactions due to fluoxetine's CYP 2D6 inhibition, which can raise drug levels.

Additional practical guidance on discontinuing and switching antidepressants can be found online.

Patient education and other management tools

Perhaps the most pragmatic and effective measure in managing ADS is to proactively educate patients about FINISH symptoms with missed doses or abrupt discontinuation. This prepares patients to better cope with ADS during planned antidepressant discontinuation and may prevent unnecessary visits to the emergency room. It is also important to reassure the patient that ADS is neither life-threatening nor indicative of addiction, and that it will eventually resolve.

If ADS does occur, the antidepressant being tapered can be rapidly resumed at the previous dosing and then tapered more slowly. This intervention is the simplest antidote and is highly effective in most cases within 24 hours.

Symptom management is another treatment strategy. For example, headaches can be managed with ibuprofen 400 mg or acetaminophen 650 mg every 4 to 6 hours. Nausea can be addressed with ondansetron 4 mg every 8 hours. Anxiety and insomnia can be managed with hydroxyzine 50 mg every 6 hours or with benzodiazipines. In some cases, diphenhydramine can be recommended if the patient is stopping a particularly anticholinergic antidepressant, such as paroxetine.

Additionally, antidepressants can have extensive drug-drug interactions. These interactions can occur from enzymatic induction or inhibition of the cytochrome P450 system or from medication side effects that overlap with the effect of other medications, such as additive effects in anticoagulation. The cessation of an antidepressant therefore requires the reevaluation of other concurrently prescribed medications. While it is always recommended to complete a medication review, changes in bupropion, fluoxetine, and paroxetine (potent CYP 2D6 inhibitors), fluvoxamine (a potent CYP 1A2 inhibitor), tricyclic and tetracyclic antidepressants, and MAOIs should prompt an especially close medication review.

FUTURE DIRECTIONS

Translational efforts including the further development of animal models for ADS are needed to enhance our understanding of the pathogenesis, phenotypic variance, and role of genetic and environmental modulation in ADS. Such efforts will help the clinician screen for a medication's potential to induce ADS and will contribute to developing agents that reduce the symptoms and severity of ADS.

TAKE-HOME POINTS

- Discontinuing or changing antidepressants, especially when done quickly, can be associated with ADS, and symptoms can emerge within hours and last for months.
- The mnemonic FINISH is useful for recognizing ADS: flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances (eg, brain zaps), and hyperarousal.
- Dosing adjustments should be made every 1 to 4 weeks and may require months to complete. Patients unable to tolerate a tapering schedule should be tapered more slowly with supplemental symptomatic management.
- Risk factors for ADS are higher dose and longer duration of treatment, medication with shorter half-life and greater receptor affinity, abrupt discontinuation, prior symptoms with missed doses or previous antidepressant discontinuations, and younger patient age.

DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.
REFERENCES

1. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71(suppl E1):e04. doi:10.4088/JCP.09s819c.04gyy

2. Van Leeuwen E, van Driel ML, Horowitz MA, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev 2021; 4(4):CD013495. doi:10.1002/14651858.CD013495.pub2

3. Keks N, Hope J, Keogh S. Switching and stopping antidepressants. Aust Prescr 2016; 39(3):76–83. doi:10.18773/austprescr.2016.039

4. Jefferson JW. Strategies for switching antidepressants to achieve maximum efficacy adolescents. J Clin Psychiatry 2008; 69(suppl E1):14–18. pmid:18494539

5. Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based? Addict Behav 2019; 97:111–121. doi:10.1016/j.addbeh.2018.08.027

6. Henssler J, Heinz A, Brandt L, Bichor T. Antidepressant withdrawal and rebound phenomena. Dtsch Arztebl Int 2019; 116(20):355–361. doi:10.3238/arztebl.2019.0355

7. Fava GA, Gatti A, Belase C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015, 84(2):72–81. doi:10.1159/000370338

8. Wilson E, Lader M. Approaches for antidepressant discontinuation. Prim Care Companion CNS Disord 2018, 80(6):19com12794. doi:10.4088/JCP.19com12794

8. Fava GA, Cosci F. Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs. J Clin Psychiatry 2019; 80(6):19com12794. doi:10.4088/JCP.19com12794

9. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44(2):77–87. doi:10.1016/0006-3223(98)00127-6

10. Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 2000; 176:363–368. doi:10.1192/bjp.176.4.363

11. Guy A, Brown M, Lewis S, Horowitz M. The ‘patient voice’: patients who experience antidepressant withdrawal symptoms are often dismissed, or misdiagnosed with relapse, or a new medical condition. Ther Adv Psychopharmacol 2020. Published November 9, 2020. doi:10.1177/2045125320976183

12. Horowitz MA, Taylor D. Tapering of SSRIs treatment to mitigate withdrawal syndromes. Lancet Psychiatry 2019; 6(6):538–546. doi:10.1016/S2215-0366(19)30322-X

13. Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry 1997; 58(suppl 7):23–27. pmid:9219490

14. Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRIs antidepressants is a challenge: management tips. Am J Psychiatry 2018; 175(12):1176–1184. doi:10.1176/appi.ajp.2018.18060692

15. University of Oxford, Oxford. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. https://study329.org/wp-content/uploads/2015/01/CSMReportonSSRISafety1.pdf. Accessed December 15, 2021.

16. Himel A, Okamura T. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome. CNS Drugs 2006; 20(8):665–672. doi:10.2165/00022830-200620080-00005

17. Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. Prim Care Companion J Clin Psychiatry 2001; 3(4):168–174. doi:10.4088/PCC.v03n0404

18. van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. Eur J Clin Pharmacol 2005; 61(4):303–307. doi:10.1007/s00028-005-0921-x

19. Phelps J. Tapering antidepressants: is 3 months slow enough? Med Hypotheses 2011; 77(6):1006–1008. doi:10.1016/j.mehy.2011.08.035

20. Hirsch M, Birnbaum RJ. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 2006; 67(suppl 4):27–30. pmid:16683860

21. Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. https://www.uptodate.com/contents/discontinuing-antidepressant-medications-in-adults. Accessed December 13, 2021.

22. Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. https://www.uptodate.com/contents/switching-antidepressant-medications-in-adults. Accessed December 13, 2021.

23. Zagrebaov KN, Kolesnikova TO, Khatsko SL, et al. Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. Eur J Pharmacol 2018; 829:129–140. doi:10.1016/j.ejphar.2018.04.003